If you have been looking for Global - Equity funds, it would not be wise to start your search with Vanguard Global Mineral Volatility Investor (VMVFX). VMVFX possesses a Zacks Mutual Fund Rank of 4 (Sell), which is based on nine forecasting factors like size, cost, and past performance.ObjectiveVMVFX is classified in the Global - Equity segment by Zacks, an area full of possibilities. Even though Global - Equity mutual funds invest in bigger markets like the U.S., Europe, and Japan, these kinds of funds aren't limited by geography. Rather, they offer an investment strategy that utilizes the global economy to provide stable returns.History of Fund/ManagerVMVFX finds itself in the Vanguard Group family, based out of Malvern, PA. Vanguard Global Mineral Volatility Investor made its debut in December of 2013, and since then, VMVFX has accumulated about $316.93 million in assets, per the most up-to-date date available. The fund is currently managed by Antonio Picca who has been in charge of the fund since November of 2018.PerformanceOf course, investors look for strong performance in funds. This fund carries a 5-year annualized total return of 8.21%, and is in the top third among its category peers. Investors who prefer analyzing shorter time frames should look at its 3-year annualized total return of 6.4%, which places it in the top third during this time-frame.When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Compared to the category average of 18.62%, the standard deviation of VMVFX over the past three years is 14.18%. Looking at the past 5 years, the fund's standard deviation is 11.37% compared to the category average of 15.15%. This makes the fund less volatile than its peers over the past half-decade.Risk FactorsInvestors should not forget about beta, an important way to measure a mutual fund's risk compared to the market as a whole. VMVFX has a 5-year beta of 0.68, which means it is likely to be less volatile than the market average. Another factor to consider is alpha, as it reflects a portfolio's performance on a risk-adjusted basis relative to a benchmark-in this case, the S&P 500. VMVFX has generated a negative alpha over the past five years of -3.29, demonstrating that managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.ExpensesFor investors, taking a closer look at cost-related metrics is key, since costs are increasingly important for mutual fund investing. Competition is heating up in this space, and a lower cost product will likely outperform its otherwise identical counterpart, all things being equal. In terms of fees, VMVFX is a no load fund. It has an expense ratio of 0.21% compared to the category average of 1.13%. VMVFX is actually cheaper than its peers when you consider factors like cost.This fund requires a minimum initial investment of $3,000, and each subsequent investment should be at least $1.Bottom LineOverall, Vanguard Global Mineral Volatility Investor ( VMVFX ) has a low Zacks Mutual Fund rank, and in conjunction with its comparatively strong performance, average downside risk, and lower fees, this fund looks like a somewhat weak choice for investors right now.Don't stop here for your research on Global - Equity funds. We also have plenty more on our site in order to help you find the best possible fund for your portfolio. Make sure to check out www.zacks.com/funds/mutual-funds for more information about the world of funds, and feel free to compare VMVFX to its peers as well for additional information. If you want to check out our stock reports as well, make sure to go to Zacks.com to see all of the great tools we have to offer, including our time-tested Zacks Rank. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (VMVFX): Fund Analysis Report To read this article on Zacks.com click here.